The Trump administration's cancellation of NIH funding for clinical trials in cancer and other diseases could have disastrous ...

Joshua Rabinowitz will direct Princeton’s role in the Weill Cancer Hub East, a collaboration with The Rockefeller University, ...

Using bacteria to fight cancer dates back to the 1860s when William B Coley, often called the father of immunotherapy, ...

Sandy Weill on Thursday announced a new $50 million donation to create a cancer research and treatment hub focused on ...

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...

Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for CLL and ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy drug, according to a study in Cancer Cell. In addition, an analysis of the ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...

The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...